GlassScriptPhysician profile
Krishna Aj Mutgi
NPI 1720346133
$108,307.67
in general payments reported to CMS, 2019-2025
36 companies · $64K in 2025
The $64K reported for 2025 was more than what 97% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $291 · 2020: $435 · 2021: $1,323 · 2022: $1,931 · 2023: $13K · 2024: $27K · 2025: $64K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $88K · Food and Beverage: $8,514 · Travel and Lodging: $7,404 · Education: $292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $88,118.50 |
| Food and Beverage | $8,514.32 |
| Travel and Lodging | $7,403.96 |
| Education | $292.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $65,472.88 | 2019-2025 | |
| Galderma Laboratories, L.P. | $26,408.50 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Chiesi USA, INC. | $6,457.51 | 2024-2025 | Filsuvez |
| Abbvie INC. | $1,981.66 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,424.87 | 2020-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $753.87 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Sun Pharmaceutical Industries INC. | $712.65 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Ucb, INC. | $617.47 | 2020-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $611.64 | 2021-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $575.23 | 2021-2025 | Sotyktu |
| Pfizer INC. | $555.10 | 2021-2025 | |
| Lilly USA, LLC | $477.28 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| Amgen INC. | $385.02 | 2020-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $368.22 | 2020-2025 | |
| Leo Pharma INC. | $322.20 | 2022-2025 | Adbry |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $193.39 | 2020-2021 | |
| Arcutis Biotherapeutics, INC. | $135.71 | 2023-2025 | Zoryve |
| Biofrontera INC. | $105.69 | 2023-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $86.25 | 2021-2023 | Arazlo, Jublia |
| Sanofi-Aventis U.S. LLC | $79.99 | 2022 | |
| Almirall LLC | $72.86 | 2022-2024 | Seysara, Klisyri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.68 | 2023-2024 | Spevigo |
| Verrica Pharmaceuticals INC. | $56.09 | 2024-2025 | Ycanth |
| Dermavant Sciences, INC. | $55.05 | 2023-2024 | Vtama |
| Organon LLC | $52.94 | 2025 | Vtama |
| Krystal Biotech INC | $48.19 | 2023-2025 | Vyjuvek |
| Botanix Sb INC | $41.04 | 2025 | Sofdra |
| Kyowa Kirin, INC. | $39.67 | 2025 | |
| Journey Medical Corporation | $34.87 | 2023 | |
| Blueprint Medicines Corporation | $27.56 | 2022 | |
| Endo Pharmaceuticals INC. | $24.92 | 2019 | |
| Celgene Corporation | $17.89 | 2019 | |
| Sandoz INC. | $15.22 | 2020 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| Merck Sharp & Dohme LLC | $11.81 | 2019 | |
| Mayne Pharma Commercial LLC | $3.58 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krishna Mutgi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.